SCHEMBL10140741

SCHEMBL10140741

[C-]#[N+]c1ccc2[nH]c(-c3c(O)c(-c4ccc(-c5cccnc5)cc4)nn3C)nc2c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.42
MAPT P10636 2/20 0.42
ALDH1A1 P00352 2/20 0.42
HPGD P15428 2/20 0.42
NPC1 O15118 1/20 0.42
STAT1 P42224 1/20 0.42
RAB9A P51151 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
LDHA P00338 1/20 0.41
EPHX2 P34913 1/20 0.41
GUSB P08236 1/20 0.41
DGAT1 O75907 1/20 0.39
KCNH2 Q12809 1/20 0.39
PDE10A Q9Y233 1/20 0.39
DHODH Q02127 1/20 0.38
KIT P10721 7/20 0.38
HTT P42858 1/20 0.38
CYP11B1 P15538 1/20 0.38
HSD17B10 Q99714 1/20 0.37
WNT1 P04628 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10140720 0.90 PDPK1 (0.39) KDM4EMAPTALDH1A1HPGDNPC1
SCHEMBL10140739 0.87 KDM4E (0.40) KDM4EMAPTALDH1A1HPGDNPC1
SCHEMBL10140703 0.84 CA12 (0.39) KDM4EMAPTALDH1A1NPC1RAB9A
SCHEMBL7975526 0.83 KIT (0.46) KDM4EMAPTALDH1A1HPGDNPC1
SCHEMBL10140745 0.83 F10 (0.46) KDM4EMAPTALDH1A1HPGDNPC1
SCHEMBL10140793 0.82 F9 (0.41) KDM4EMAPTALDH1A1HPGDNPC1
SCHEMBL10140767 0.81 NPC1 (0.43) KDM4EALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL10140046 0.81 KDM4E (0.43) KDM4EMAPTALDH1A1HPGDNPC1
SCHEMBL10140455 0.79 AMY1A (0.44) KDM4EMAPTALDH1A1HPGDNPC1
SCHEMBL10140025 0.79 MAPT (0.45) KDM4EMAPTALDH1A1HPGDNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8148363-B2 Heterocyclic compounds as factor IXA inhibitors SCHERING CORPORATION (US) 2012-04-03 US disclosed
US-20110065682-A1 HETEROCYCLIC COMPOUNDS AS FACTOR IXA INHIBITORS MERCK SHARP & DOHME LLC 2011-03-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065682-A1 HETEROCYCLIC COMPOUNDS AS FACTOR IXA INHIBITORS F9, F12, F8 KDM4E 1387/4885MAPT 4510/4885ALDH1A1 1022/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.